$GNSZ News: Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation

SAN ANTONIO, Texas, July 14, 2014 - GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces that Kareg Corporation\'s Director of Research, Sheldon S. Traube, has issued the following research report on the company.



Sheldon S. Traube, Director of Research, Kareg Corporation, Initiating Coverage with a Speculative Buy Recommendation



Read the full report: http://www.genspera.com/press/140711_Genspera_research_report_July2014.pdf



GNSZ is attractive for speculative accounts seeking above-average appreciation potential based upon the following considerations:



Summary and Conclusion:

1. GenSpera is focused on the development of prodrug cancer therapeutics based on a novel breakthrough proprietary technology platform which supports the development of a suite of drug compounds targeted at different cancer indications, as well as imaging applications. GenSpera's approach is supported by over $35M of funding ($15 million via various grants to Johns Hopkins and more than $20 million by the Company) and 15 years of research at Johns Hopkins Medical Center and other renowned research centers.



2. Its unique cytotoxin kills cancer cells independent of cell division and is expected to eradicate cancer stem cells as well as slow and fast growing cancers.



3. Its tumor-specific activation of drug minimizes side-effects normally experienced with other cancer drug compounds. Traditional and emerging treatments for many late stage cancers struggle with potency issues and/or side effects. Traditional therapies typically have serious side effects, face resistance, and have minimal effectiveness on slowly dividing cancer cells. Antibody drugs target high antigen expressing cells and generally have a lower probability of tumor kill. Anti-Angiogenesis compounds typically offer limited survival benefits and cause serious side effects.



4. GenSpera's drug candidates are based on chemical derivatives of a plant cytotoxin, called Thapsigargin, which is a potent inhibitor of the intracellular sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) pump. The inhibition of the transport protein causes intracellular Ca2+ (calcium)...